These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1017 related items for PubMed ID: 17641982

  • 1. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I, Weiss NS, Lin DW, Stanford JL.
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [Abstract] [Full Text] [Related]

  • 2. The effectiveness of screening for prostate cancer: a nested case-control study.
    Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P.
    Arch Intern Med; 2006 Jan 09; 166(1):38-43. PubMed ID: 16401808
    [Abstract] [Full Text] [Related]

  • 3. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, PLCO Project Team.
    J Natl Cancer Inst; 2005 Mar 16; 97(6):433-8. PubMed ID: 15770007
    [Abstract] [Full Text] [Related]

  • 4. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G.
    Can J Urol; 2005 Feb 16; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [Abstract] [Full Text] [Related]

  • 5. Associations of demographic and health-related characteristics with prostate cancer screening in Washington State.
    Close DR, Kristal AR, Li S, Patterson RE, White E.
    Cancer Epidemiol Biomarkers Prev; 1998 Jul 16; 7(7):627-30. PubMed ID: 9681532
    [Abstract] [Full Text] [Related]

  • 6. Characteristics of prostate cancer detected by digital rectal examination only.
    Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ.
    Urology; 2007 Dec 16; 70(6):1117-20. PubMed ID: 18158030
    [Abstract] [Full Text] [Related]

  • 7. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct 16; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 8. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ, Etzioni R, Vessella RL, Hu C, Goodman GE.
    J Urol; 2001 Jul 16; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [Abstract] [Full Text] [Related]

  • 9. Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium.
    Arch Intern Med; 1995 Feb 27; 155(4):389-92. PubMed ID: 7531426
    [Abstract] [Full Text] [Related]

  • 10. Digital rectal examination is barrier to population-based prostate cancer screening.
    Nagler HM, Gerber EW, Homel P, Wagner JR, Norton J, Lebovitch S, Phillips JL.
    Urology; 2005 Jun 27; 65(6):1137-40. PubMed ID: 15922431
    [Abstract] [Full Text] [Related]

  • 11. Factors influencing use of the prostate-specific antigen screening test in primary care.
    Moran WP, Cohen SJ, Preisser JS, Wofford JL, Shelton BJ, McClatchey MW.
    Am J Manag Care; 2000 Mar 27; 6(3):315-24. PubMed ID: 10977432
    [Abstract] [Full Text] [Related]

  • 12. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?
    Philip J, Dutta Roy S, Ballal M, Foster CS, Javlé P.
    BJU Int; 2005 May 27; 95(7):969-71. PubMed ID: 15839915
    [Abstract] [Full Text] [Related]

  • 13. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS, Sherin K, ACPM Prevention Practice Committee.
    Am J Prev Med; 2008 Feb 27; 34(2):164-70. PubMed ID: 18201648
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ.
    Urology; 2008 May 27; 71(5):787-91. PubMed ID: 18267334
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Misclassifying the indications for prostate-specific antigen testing may bias case-control studies of the efficacy of prostate cancer screening.
    Hoffman RM, Adams-Cameron ML, Murata GH.
    J Clin Epidemiol; 2004 Oct 27; 57(10):1071-5. PubMed ID: 15528058
    [Abstract] [Full Text] [Related]

  • 19. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA.
    J Clin Oncol; 2007 Jul 20; 25(21):3076-81. PubMed ID: 17634486
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.